Reprogramming the Tumor Microenvironment: A New Era for Viro-Immunotherapy

Oncolytic virus therapy, such as herpes simplex virus 1 (oHSV), has shown promising results in treating cancers like glioblastoma (GBM) and breast cancer brain metastases (BCBM). However, its effectiveness is often limited by the resistance of tumor cells and their microenvironment (TME). A major breakthrough has identified the growth factor IGF2, induced by oHSV, as a key player in this resistance. This study introduces oHSV-D11mt, a next-generation oncolytic virus designed to neutralize IGF2 and remodel the TME to enhance anti-tumor immune responses.